Demethylation of tumor necrosis factor-? converting enzyme predicts poor prognosis in acute-on-chronic hepatitis B liver failure - 17/09/16
pages | 8 |
Iconographies | 5 |
Vidéos | 0 |
Autres | 0 |
Summary |
Background and objective |
Tumor necrosis factor-α converting enzyme (TACE) has been demonstrated to be involved in liver inflammation. However, the significance of TACE methylation in acute-on-chronic hepatitis B liver failure (ACHBLF) has not been demonstrated. This study aims to evaluate TACE methylation status in ACHBLF and determine its predictive value for prognosis.
Methods |
Forty-five patients with ACHBLF, 80 with chronic hepatitis B (CHB) and 54 healthy controls (HCs) were enrolled. The methylation status of TACE promoter was determined by methylation-specific polymerase chain reaction. The TACE mRNA expression was determined by quantitative real-time polymerase chain reaction. The plasma levels of TACE, TNF-α, sTNFRI, sTNFRII were measured by enzyme-linked immunosorbent assay.
Results |
TACE methylation was significantly lower in patients with ACHBLF than those with CHB (χ2=24.69, P<0.01) and HCs (χ2=35.93, P<0.01). Meanwhile, TACE methylation was significantly lower in CHB patients than HCs (χ2=4.03, P<0.05). TACE methylation was significantly inversely associated with its mRNA expression (r=−0.68; P<0.01). The plasma levels of TACE, TNF-α, sTNFRI, sTNFRII were significantly higher in patients with ACHBLF than those with CHB (P<0.05, respectively) and HCs (P<0.05, respectively). In patients with ACHBLF, significantly higher prothrombin activity, lower total bilirubin and MELD score were found in TACE methylated group than unmethylated group (P<0.05). ACHBLF patients with methylated TACE showed significantly better survival than those without (P<0.01).
Conclusion |
This study showed that demethylation of TACE promoter occurred in ACHBLF and might serve as a potential prognostic marker.
Le texte complet de cet article est disponible en PDF.Plan
Vol 40 - N° 4
P. 457-464 - septembre 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?